BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gui CH, Baey S, D'cruz RT, Shelat VG. Trans-arterial chemoembolization + radiofrequency ablation versus surgical resection in hepatocellular carcinoma - A meta-analysis. Eur J Surg Oncol 2020;46:763-71. [PMID: 31937433 DOI: 10.1016/j.ejso.2020.01.004] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Wu G, Li J, Li C, Ou X, Feng K, Xia F, Chen Z, Zhang L, Ma K. Long‐term efficacy of no‐touch radiofrequency ablation in the treatment of single small hepatocellular carcinoma: A single center long‐term follow‐up study. Cancer Medicine 2022. [DOI: 10.1002/cam4.5428] [Reference Citation Analysis]
2 Sim JZT, Hui TCH, Chuah TK, Low HM, Tan CH, Shelat VG. Efficacy of texture analysis of pre-operative magnetic resonance imaging in predicting microvascular invasion in hepatocellular carcinoma. World J Clin Oncol 2022; 13(11): 918-928 [DOI: 10.5306/wjco.v13.i11.918] [Reference Citation Analysis]
3 Goyal P, Salem R, Mouli SK. Role of interventional oncology in hepatocellular carcinoma: Future best practice beyond current guidelines. BJR 2022;95. [DOI: 10.1259/bjr.20220379] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chen L, Zhang W, Sun T, Ren Y, Sun B, Zhu L, Zhao H, Zheng C. Effect of Transarterial Chemoembolization Plus Percutaneous Ethanol Injection or Radiofrequency Ablation for Liver Tumors. J Hepatocell Carcinoma 2022;9:783-97. [PMID: 35983562 DOI: 10.2147/JHC.S370486] [Reference Citation Analysis]
5 Zhang S, Zhang N, Zhu W, Liu T, Lv J, Jiang W, Zhang Y, Song T, Zhang L, Xie Y, Zhou Y, Lu W. A Novel Nomogram Model to Predict the Recurrence-Free Survival and Overall Survival of Hepatocellular Carcinoma. Front Oncol 2022;12:946531. [DOI: 10.3389/fonc.2022.946531] [Reference Citation Analysis]
6 Dan Y, Meng W, Li W, Chen Z, Lyu Y, Yu T. Transarterial Chemoembolization Combined With Radiofrequency Ablation Versus Hepatectomy for Hepatocellular Carcinoma: A Meta-Analysis. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.948355] [Reference Citation Analysis]
7 Luerken L, Haimerl M, Doppler M, Uller W, Beyer LP, Stroszczynski C, Einspieler I. Update on Percutaneous Local Ablative Procedures for the Treatment of Hepatocellular Carcinoma. Rofo 2022. [PMID: 35545102 DOI: 10.1055/a-1768-0954] [Reference Citation Analysis]
8 Xia F, Ndhlovu E, Liu Z, Chen X, Zhang B, Zhu P, Liu Z. Alpha-Fetoprotein+Alkaline Phosphatase (A-A) Score Can Predict the Prognosis of Patients with Ruptured Hepatocellular Carcinoma Underwent Hepatectomy. Disease Markers 2022;2022:1-16. [DOI: 10.1155/2022/9934189] [Reference Citation Analysis]
9 Yang XG, Huang YC, Wang CH, Sun YY, Huang Z, Xu GH. Predictive Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization Combined with Radiofrequency Ablation. Cancer Invest 2022;:1-31. [PMID: 35404178 DOI: 10.1080/07357907.2022.2065508] [Reference Citation Analysis]
10 Sheriff S, Madhavan S, Lei GY, Chan YH, Junnarkar SP, Huey CW, Low JK, Shelat VG. Predictors of mortality within the first year post-hepatectomy for hepatocellular carcinoma. J Egypt Natl Canc Inst 2022;34:14. [PMID: 35368234 DOI: 10.1186/s43046-022-00113-8] [Reference Citation Analysis]
11 Yang S, Lin H, Song J. Efficacy and safety of various primary treatment strategies for very early and early hepatocellular carcinoma: a network meta-analysis. Cancer Cell Int 2021;21:681. [PMID: 34923980 DOI: 10.1186/s12935-021-02365-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Sparchez Z, Radu P, Bartos A, Nenu I, Craciun R, Mocan T, Horhat A, Spârchez M, Dufour JF. Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines? World J Gastrointest Oncol 2021; 13(12): 1896-1918 [DOI: 10.4251/wjgo.v13.i12.1896] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Lu J, Zhao M, Arai Y, Zhong BY, Zhu HD, Qi XL, de Baere T, Pua U, Yoon HK, Madoff DC, Teng GJ; International Society of Multidisciplinary Interventional Oncology (ISMIO). Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO). Hepatobiliary Surg Nutr 2021;10:661-71. [PMID: 34760969 DOI: 10.21037/hbsn-21-260] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
14 Li HZ, Tan J, Tang T, An TZ, Li JX, Xiao YD. Chemoembolization Plus Microwave Ablation vs Chemoembolization Alone in Unresectable Hepatocellular Carcinoma Beyond the Milan Criteria: A Propensity Scoring Matching Study. J Hepatocell Carcinoma 2021;8:1311-22. [PMID: 34754838 DOI: 10.2147/JHC.S338456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Li Z, Li Q, Wang X, Chen W, Jin X, Liu X, Ye F, Dai Z, Zheng X, Li P, Sun C, Liu X, Zhang Q, Luo H, Liu R. Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta-analysis. Cancer Med 2021. [PMID: 34655179 DOI: 10.1002/cam4.4350] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
16 Bo XW, Sun LP, Yu SY, Xu HX. Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions. World J Gastrointest Oncol 2021; 13(10): 1397-1411 [PMID: 34721773 DOI: 10.4251/wjgo.v13.i10.1397] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Bucalau AM, Tancredi I, Verset G. In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play? Cancers (Basel) 2021;13:5129. [PMID: 34680278 DOI: 10.3390/cancers13205129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhang YJ, Chen MS, Chen Y, Lau WY, Peng Z. Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma. JAMA Netw Open 2021;4:e2126992. [PMID: 34570206 DOI: 10.1001/jamanetworkopen.2021.26992] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
19 Suwa K, Seki T, Aoi K, Yamashina M, Murata M, Yamashiki N, Nishio A, Shimatani M, Naganuma M. Efficacy of microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score analysis. Abdom Radiol (NY) 2021;46:3790-7. [PMID: 33675382 DOI: 10.1007/s00261-021-03008-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Chan KS, Shelat VG. Clinical Utility of Advances in Radiofrequency Ablation for Small Hepatocellular Carcinoma. J Invest Surg 2021;:1-3. [PMID: 34240665 DOI: 10.1080/08941939.2021.1944404] [Reference Citation Analysis]
21 Bai XM, Yang W. Radiofrequency ablation of hepatocellular carcinoma: Prognostic factors and recent advances. Shijie Huaren Xiaohua Zazhi 2021; 29(13): 677-683 [DOI: 10.11569/wcjd.v29.i13.677] [Reference Citation Analysis]
22 Cao G, Liu Y, Li L, Zhao X, Liu R, Liu J, Liu J, Cao H. A Comparison of Adverse Events Among Radiofrequency Ablation, Conventional Transarterial Chemoembolization (TACE) and Drug-Eluting Bead TACE in Treating Hepatocellular Carcinoma Patients. Cancer Manag Res 2021;13:5373-82. [PMID: 34262345 DOI: 10.2147/CMAR.S308097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Pan YX, Sun XQ, Hu ZL, Xie W, Nie KX, Fang AP, Zhang YY, Fu YZ, Chen JB, Wang JC, Wang X, Zhang YJ, Hu DD, Chen MS. Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients. J Hepatocell Carcinoma 2021;8:657-70. [PMID: 34235104 DOI: 10.2147/JHC.S316223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Zhao H, Zhang L, Chen H. Liver stiffness measured by magnetic resonance elastography in early recurrence of hepatocellular carcinoma after treatment: A protocol for systematic review and meta analysis. Medicine (Baltimore) 2021;100:e26183. [PMID: 34115001 DOI: 10.1097/MD.0000000000026183] [Reference Citation Analysis]
25 Zhang YF, Lu LH, Zhong C, Chen MS, Guo RP, Wang L. Prognostic Value of the Preoperative Lymphocyte-C-Reactive Protein Ratio in Hepatocellular Carcinoma Patients Treated with Curative Intent: A Large-Scale Multicentre Study. J Inflamm Res 2021;14:2483-95. [PMID: 34140796 DOI: 10.2147/JIR.S311994] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
26 Qu C, Li XQ, Li C, Xia F, Feng K, Ma K. The Short-Term Efficacy of Novel No-Touch Combined Directional Perfusion Radiofrequency Ablation in the Treatment of Small Hepatocellular Carcinoma with Cirrhosis. J Invest Surg 2021;:1-8. [PMID: 34085878 DOI: 10.1080/08941939.2021.1931575] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
27 Sheriff S, Madhavan S, Lei G, Chan YH, Junnarkar SP, Huey C, Low J, Shelat VG. Predictors of mortality within the first year post-hepatectomy for hepatocellular carcinoma (Preprint).. [DOI: 10.2196/preprints.30848] [Reference Citation Analysis]
28 Feng JK, Sun JX, Liu ZH, Gu JW, Chen ZH, Liu C, Guo WX, Shi J, Cheng SQ. Efficacy and Safety of Transarterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma Associated with Bile Duct Tumor Thrombus: A Real-World Retrospective Cohort Study. Cancer Manag Res 2021;13:3551-60. [PMID: 33953609 DOI: 10.2147/CMAR.S307065] [Reference Citation Analysis]
29 Zhang YF, Shi M, Lu LH, Wang L, Guo RP. Selecting an Optimal Staging System for Intermediate-Stage Hepatocellular Carcinoma: Comparison of 9 Currently Used Prognostic Models. J Hepatocell Carcinoma 2021;8:253-61. [PMID: 33907695 DOI: 10.2147/JHC.S305581] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Mai RY, Zeng J, Meng WD, Lu HZ, Liang R, Lin Y, Wu GB, Li LQ, Ma L, Ye JZ, Bai T. Artificial neural network model to predict post-hepatectomy early recurrence of hepatocellular carcinoma without macroscopic vascular invasion. BMC Cancer 2021;21:283. [PMID: 33726693 DOI: 10.1186/s12885-021-07969-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
31 Huang J, Yang Y, Xia Y, Liu FC, Liu L, Zhu P, Yuan SX, Gu FM, Fu SY, Zhou WP, Liu H, Jiang BG, Pan ZY. Prediction of Patient Survival Following Hepatic Resection in Early-Stage Hepatocellular Carcinoma with Indexed Ratios of Aspartate Aminotransferase to Platelets: A Retrospective Cohort Study. Cancer Manag Res 2021;13:1733-46. [PMID: 33642875 DOI: 10.2147/CMAR.S284950] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Pang Q, Liu S, Wang L, Pan H, Wang C, Zhou L, Lu Y, Liu H. The Significance of Platelet-Albumin-Bilirubin (PALBI) Grade in Hepatocellular Carcinoma Patients Stratified According to Platelet Count. Cancer Manag Res 2020;12:12811-22. [PMID: 33364830 DOI: 10.2147/CMAR.S277013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
33 Lei GY, Shen L, Junnarkar SP, Huey CT, Low J, Shelat VG. Predictors of 90-Day Mortality following Hepatic Resection for Hepatocellular Carcinoma. Visc Med 2021;37:102-9. [PMID: 33981750 DOI: 10.1159/000510811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
34 Li Y, Li Z, Deng K, Liao M, Yuan S, Huang Z. Fibrinogen/Lymphocyte Count Ratio Can Be Used as a New Indicator of Prognosis in Patients with Hepatocellular Carcinoma After Radical Resection. Cancer Manag Res 2020;12:9057-66. [PMID: 33061600 DOI: 10.2147/CMAR.S266653] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Shelat VG. Role of inflammatory indices in management of hepatocellular carcinoma-neutrophil to lymphocyte ratio. Ann Transl Med 2020;8:912. [PMID: 32953712 DOI: 10.21037/atm-2020-90] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
36 Li C, Xu J. Identification of Potentially Therapeutic Target Genes of Hepatocellular Carcinoma. Int J Environ Res Public Health 2020;17:E1053. [PMID: 32046048 DOI: 10.3390/ijerph17031053] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]